Here is what I don't get and maybe someone can explain:
They had the valuation of NGIO and it was AT LEAST 500 million, so we know for a fact it is more than 500 million. Ok, so, with the number of shares outstanding, we now know the PPS would be at least 5.00 PPS, which is exactly what Joe wanted it to be.
With that being said, then what exactly is the hold up for listing? The PPS would be at least 5.00 which is what Joe wants, the valuation is over 500 million. With the deals out there and the positives in the China deal, the listing of NGIO should actually get a boost from investors on NASDAQ, especially when looking at the overall prospects.
If you actually step back and look at this, it makes no sense not to list NGIO.
Generex Biotechnology Corp. (GNBT) Stock Research Links